Clinical trials
Recruiting Multiple Myeloma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
509 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 15 |
| 2020 | 13 |
| 2021 | 25 |
| 2022 | 43 |
| 2023 | 79 |
| 2024 | 96 |
| 2025 | 115 |
| 2026 | 92 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 509 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 14 |
| Memorial Sloan Kettering Cancer Center | 13 |
| Janssen Research & Development, LLC | 11 |
| Mayo Clinic | 10 |
| National Cancer Institute (NCI) | 9 |
| Regeneron Pharmaceuticals | 9 |
| M.D. Anderson Cancer Center | 7 |
| Washington University School of Medicine | 7 |
| AbbVie | 6 |
| AstraZeneca | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 509 |
| Recurrence | 52 |
| Lymphoma | 40 |
| Lymphoma, Non-Hodgkin | 30 |
| Neoplasms | 30 |
| Hematologic Neoplasms | 27 |
| Leukemia, Myeloid, Acute | 24 |
| Myelodysplastic Syndromes | 24 |
| Leukemia | 23 |
| Neoplasms, Plasma Cell | 23 |
Trials
Showing 26 to 50 of 509. Each trial links to its page on Pharma Observatory.
409 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.